Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2017 | Pages:
84 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Peanut Allergy - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peanut Allergy - Pipeline Review, H1 2017, provides an overview of the Peanut Allergy (Immunology) pipeline landscape. Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mild to severe. Peanut allergy signs and symptoms can include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peanut Allergy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Peanut Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Peanut Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4, 8 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Discovery stages comprises 1, 1 and 1 molecules, respectively. Peanut Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Peanut Allergy (Immunology). - The pipeline guide reviews pipeline therapeutics for Peanut Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Peanut Allergy (Immunology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Peanut Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Peanut Allergy (Immunology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Peanut Allergy (Immunology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Peanut Allergy (Immunology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Peanut Allergy - Overview Peanut Allergy - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Peanut Allergy - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Peanut Allergy - Companies Involved in Therapeutics Development Adverum Biotechnologies Inc Aimmune Therapeutics Inc Alfacyte Ltd Allergy Therapeutics Plc AnaptysBio Inc ASIT Biotech SA Astellas Pharma Inc BioLingus AG DBV Technologies SA HAL Allergy BV Intrommune Therapeutics Sanofi Peanut Allergy - Drug Profiles aldesleukin - Drug Profile Product Description Mechanism Of Action R&D Progress Allergen for Peanut Allergy - Drug Profile Product Description Mechanism Of Action R&D Progress Allergen for Peanut Allergy - Drug Profile Product Description Mechanism Of Action R&D Progress Allergen for Peanut Allergy - Drug Profile Product Description Mechanism Of Action R&D Progress Allergen for Peanut Allergy - Drug Profile Product Description Mechanism Of Action R&D Progress ANB-020 - Drug Profile Product Description Mechanism Of Action R&D Progress ANN-004 - Drug Profile Product Description Mechanism Of Action R&D Progress AR-101 - Drug Profile Product Description Mechanism Of Action R&D Progress ASP-0892 - Drug Profile Product Description Mechanism Of Action R&D Progress DBV-712 - Drug Profile Product Description Mechanism Of Action R&D Progress Drugs to Inhibit CYP11A1 for Peanut Allergy and Asthma - Drug Profile Product Description Mechanism Of Action R&D Progress HALMPE-1 - Drug Profile Product Description Mechanism Of Action R&D Progress INT-301 - Drug Profile Product Description Mechanism Of Action R&D Progress PER-1080 - Drug Profile Product Description Mechanism Of Action R&D Progress pnut-ASIT - Drug Profile Product Description Mechanism Of Action R&D Progress Polyvac Peanut - Drug Profile Product Description Mechanism Of Action R&D Progress SAR-439794 - Drug Profile Product Description Mechanism Of Action R&D Progress SCV-204 - Drug Profile Product Description Mechanism Of Action R&D Progress SCV-209 - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine 2 for Peanut Allergy - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine for Peanut Allergy - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine for Peanut Allergy - Drug Profile Product Description Mechanism Of Action R&D Progress VTC-064 - Drug Profile Product Description Mechanism Of Action R&D Progress Peanut Allergy - Dormant Projects Peanut Allergy - Discontinued Products Peanut Allergy - Product Development Milestones Featured News & Press Releases Mar 10, 2017: DBV Technologies Announces Completion of Enrollment of the REALISE Study in Peanut Allergic Children Mar 06, 2017: Aimmune Therapeutics Presents Clinical Data on Phase 3 Screening and Phase 2 Adherence for AR101 for Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting Mar 05, 2017: Data at AAAAI 2017 Show Lasting Response and Favorable Safety Profile of Investigational Agent, Viaskin Peanut, Throughout Three Years of Treatment of Peanut Allergic Children Mar 04, 2017: AnaptysBio Announces Data from Scientific Collaboration with the Benaroya Research Institute Presented at the AAAAI 2017 Annual Meeting Feb 27, 2017: Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting Feb 16, 2017: Aimmune Therapeutics Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback Feb 06, 2017: Selecta Biosciences Presents Preclinical Data Regarding SVP-Enabled Peanut Allergy Therapeutic Vaccine Feb 01, 2017: Allergy Therapeutics Announces Positive Efficacy and Safety Data Shown in Peanut Allergy Vaccine Dec 20, 2016: Astellas Announces FDA Fast Track Designation for ASP0892, DNA Vaccine for Mitigation of Severe Hypersensitivity Reactions due to Peanut Allergy Dec 13, 2016: AnaptysBio Announces Clearance of U.S. IND and U.K. CTA for ANB020 Nov 28, 2016: Aimmune Therapeutics Completes Global Enrollment of Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy Nov 11, 2016: DBV Technologies Announces Poster Presentations at the 2016 American College of Allergy, Asthma, and Immunology Meeting Oct 26, 2016: DBV Technologies Announces Publication of Positive Viaskin Peanut Data From NIAID-Sponsored Phase II Academic Study in the Journal of Allergy and Clinical Immunology Oct 24, 2016: Topline Results from Two-Year Follow-Up Study of Viaskin Peanut Show Long-Lasting and High Levels of Desensitization to Peanut Oct 03, 2016: AnaptysBio Reports ANB020 Top-Line Phase 1 Clinical Trial Results Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Peanut Allergy, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Peanut Allergy - Pipeline by Adverum Biotechnologies Inc, H1 2017 Peanut Allergy - Pipeline by Aimmune Therapeutics Inc, H1 2017 Peanut Allergy - Pipeline by Alfacyte Ltd, H1 2017 Peanut Allergy - Pipeline by Allergy Therapeutics Plc, H1 2017 Peanut Allergy - Pipeline by AnaptysBio Inc, H1 2017 Peanut Allergy - Pipeline by ASIT Biotech SA, H1 2017 Peanut Allergy - Pipeline by Astellas Pharma Inc, H1 2017 Peanut Allergy - Pipeline by BioLingus AG, H1 2017 Peanut Allergy - Pipeline by DBV Technologies SA, H1 2017 Peanut Allergy - Pipeline by HAL Allergy BV, H1 2017 Peanut Allergy - Pipeline by Intrommune Therapeutics, H1 2017 Peanut Allergy - Pipeline by Sanofi, H1 2017 Peanut Allergy - Dormant Projects, H1 2017 Peanut Allergy - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
